COSM News & Events

Cosmos Health announced that its wholly-owned subsidiary, Cana Laboratories, has received new contract manufacturing orders from Nassington and Verisfield for a combined 253,657 units across a range of medicines and other pharmaceutical products. Under the orders, Cana will manufacture Gritse oral solution 0.4 mg/ml; Gritse forte oral solution 2 mg/ml; Gritse forte oral solution 4 mg/ml; Fungofort cutaneous spray, solution; Paco-4 tablets; dexamethasone 2 mg/5 ml, in 50 ml and 150 ml bottle and oral solution presentations; and Foproct rectal cream.

Cosmos Health announced that it has entered into a non-binding letter of intent to acquire 100% of Doc Pharma, a fully licensed GMP pharmaceutical manufacturer. The company expects the proposed transaction to be accretive and to enhance its asset base, revenue, margins, and cash flow over time. Doc Pharma brings an approximately $24M asset base. Doc Pharma generated approximately $6.7M in three-year average annual revenue. Doc Pharma generated approximately $3.2M in three-year average annual gross profit. Doc Pharma is a related-party entity, and the proposed acquisition constitutes a related-party transaction. As such, the proposed transaction will be reviewed by a committee of independent directors, supported by an independent fairness opinion and valuation, as well as a PCAOB audit, and will be subject to shareholder approval.